Arbutus Biopharma Stock Forecast, Price & News

Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

Is Arbutus Biopharma a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arbutus Biopharma stock.
View analyst ratings for Arbutus Biopharma or view top-rated stocks.

What stocks does MarketBeat like better than Arbutus Biopharma?

Wall Street analysts have given Arbutus Biopharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arbutus Biopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Arbutus Biopharma?

Arbutus Biopharma saw a decline in short interest in the month of September. As of September 30th, there was short interest totaling 2,780,000 shares, a decline of 24.9% from the September 15th total of 3,700,000 shares. Based on an average daily volume of 2,340,000 shares, the days-to-cover ratio is presently 1.2 days. Currently, 3.5% of the company's shares are short sold.
View Arbutus Biopharma's Short Interest.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Arbutus Biopharma.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) released its quarterly earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.02. The biopharmaceutical company earned $2.33 million during the quarter, compared to the consensus estimate of $2.07 million.
View Arbutus Biopharma's earnings history.

How has Arbutus Biopharma's stock been impacted by COVID-19?

Arbutus Biopharma's stock was trading at $2.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ABUS shares have increased by 58.1% and is now trading at $4.08.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ABUS?

4 equities research analysts have issued twelve-month target prices for Arbutus Biopharma's shares. Their forecasts range from $5.00 to $10.00. On average, they expect Arbutus Biopharma's share price to reach $6.75 in the next twelve months. This suggests a possible upside of 65.4% from the stock's current price.
View analysts' price targets for Arbutus Biopharma or view top-rated stocks among Wall Street analysts.

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the following people:

• William H. Collier, President, Chief Executive Officer & Director
• David C. Hastings, Chief Financial & Accounting Officer
• Michael J. Sofia, Chief Scientific Officer
• Elizabeth Howard, Secretary, Chief Compliance Officer & EVP
• Michael J. McElhaugh, Chief Business Officer

What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?

6 employees have rated Arbutus Biopharma CEO Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among Arbutus Biopharma's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Arbutus Biopharma's key competitors?

Some companies that are related to Arbutus Biopharma include Avid Bioservices (CDMO), MorphoSys (MOR), NGM Biopharmaceuticals (NGM), Bicycle Therapeutics (BCYC), Axsome Therapeutics (AXSM), Centessa Pharmaceuticals (CNTA), Kadmon (KDMN), Travere Therapeutics (TVTX), PureTech Health (PRTC), Protagonist Therapeutics (PTGX), Enanta Pharmaceuticals (ENTA), Madrigal Pharmaceuticals (MDGL), Organogenesis (ORGO), uniQure (QURE) and Xenon Pharmaceuticals (XENE).
View all of ABUS's competitors.

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $4.08.

How much money does Arbutus Biopharma make?

Arbutus Biopharma has a market capitalization of $404.58 million and generates $6.91 million in revenue each year. The biopharmaceutical company earns $-63.74 million in net income (profit) each year or ($1.00) on an earnings per share basis.

How many employees does Arbutus Biopharma have?

Arbutus Biopharma employs 77 workers across the globe.

When was Arbutus Biopharma founded?

Arbutus Biopharma was founded in 1992.

What is Arbutus Biopharma's official website?

The official website for Arbutus Biopharma is www.arbutusbio.com.

Where are Arbutus Biopharma's headquarters?

Arbutus Biopharma is headquartered at 701 VETERANS CIRCLE, WARMINSTER PA, 18974.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The biopharmaceutical company can be reached via phone at (267) 469-0914 or via email at [email protected].